{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:06Z","timestamp":1793316246172,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s11060-016-2054-8","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T15:14:29Z","timestamp":1454339669000},"page":"505-514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II\/III gliomas treated with temozolomide"],"prefix":"10.1007","volume":"127","author":[{"given":"Navid","family":"Redjal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Reinshagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Walcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian V.","family":"Nahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"issue":"Suppl 4","key":"2054_CR1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/neuonc\/nou223","volume":"16","author":"QT Ostrom","year":"2014","unstructured":"Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 16(Suppl 4):63. doi: 10.1093\/neuonc\/nou223","journal-title":"Neuro Oncol"},{"key":"2054_CR2","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(11)61346-9","volume":"379","author":"D Ricard","year":"2012","unstructured":"Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre J-YY (2012) Primary brain tumours in adults. Lancet 379:1984\u20131996. doi: 10.1016\/S0140-6736(11)61346-9","journal-title":"Lancet"},{"issue":"6","key":"2054_CR3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1750-3639.2011.00491.x","volume":"21","author":"V Rigau","year":"2011","unstructured":"Rigau V, Zouaoui S, Mathieu-Daud\u00e9 H, Darlix A, Maran A, Tr\u00e9tarre B, Bessaoud F, Bauchet F, Attaoua R, Fabbro-Peray P, Fabbro M, Kerr C, Taillandier L, Duffau H, Figarella-Branger D, Costes V, Bauchet L, Soci\u00e9t\u00e9 Fran\u00e7aise de Neuropathologie SFdN, Club de Neuro-Oncologie of the Soci\u00e9t\u00e9 Fran\u00e7aise de N, Association des Neuro-Oncologues d\u2019Expression Fran\u00e7aise (ANOCEF) (2011) French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol 21(6):633\u2013644. doi: 10.1111\/j.1750-3639.2011.00491.x","journal-title":"Brain Pathol"},{"key":"2054_CR4","first-page":"140","volume":"3","author":"DA Hardesty","year":"2011","unstructured":"Hardesty DA, Sanai N (2011) The value of glioma extent of resection in the modern neurosurgical era. Front Neurol 3:140. doi: 10.3389\/fneur.2012.00140","journal-title":"Front Neurol"},{"key":"2054_CR5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","volume":"95","author":"M Lacroix","year":"2001","unstructured":"Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190\u2013198. doi: 10.3171\/jns.2001.95.2.0190","journal-title":"J Neurosurg"},{"key":"2054_CR6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff R-OO, for, of, Groups E, of Group N (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466. doi: 10.1016\/S1470-2045(09)70025-7","journal-title":"Lancet Oncol"},{"key":"2054_CR7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine 352:987\u2013996. doi: 10.1056\/NEJMoa043330","journal-title":"The New England journal of medicine"},{"issue":"Suppl 1","key":"2054_CR8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1227\/NEU.0000000000000390","volume":"61","author":"RL Price","year":"2014","unstructured":"Price RL, Chiocca EA (2014) Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. Neurosurgery 61(Suppl 1):74\u201383. doi: 10.1227\/NEU.0000000000000390","journal-title":"Neurosurgery"},{"key":"2054_CR9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-3-319-12048-5_5","volume":"163","author":"P Kumthekar","year":"2015","unstructured":"Kumthekar P, Raizer J, Singh S (2015) Low-grade glioma. Cancer Treat Res 163:75\u201387. doi: 10.1007\/978-3-319-12048-5_5","journal-title":"Cancer Treat Res"},{"key":"2054_CR10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11910-010-0105-7","volume":"10","author":"N Pouratian","year":"2010","unstructured":"Pouratian N, Schiff D (2010) Management of low-grade glioma. Curr Neurol Neurosci Rep 10:224\u2013231. doi: 10.1007\/s11910-010-0105-7","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2054_CR11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11864-014-0304-6","volume":"15","author":"A Tandon","year":"2014","unstructured":"Tandon A, Schiff D (2014) Therapeutic decision making in patients with newly diagnosed low grade glioma. Curr Treat Options Oncol 15:529\u2013538. doi: 10.1007\/s11864-014-0304-6","journal-title":"Curr Treat Options Oncol"},{"key":"2054_CR12","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","volume":"17","author":"WK Yung","year":"1999","unstructured":"Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O\u2019Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762\u20132771","journal-title":"J Clin Oncol"},{"key":"2054_CR13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-3-211-99481-8_8","volume":"35","author":"M Klein","year":"2009","unstructured":"Klein M (2009) Health-related quality of life aspects in patients with low-grade glioma. Adv Tech Stand Neurosurg 35:213\u2013235","journal-title":"Adv Tech Stand Neurosurg"},{"key":"2054_CR14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","volume":"366","author":"MJ Bent van den","year":"2004","unstructured":"van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstr\u00f6m POO, Collette L, Pi\u00e9rart M, Mirimanoff R, Karim AB, Radiotherapy E, Brain Tumor G, The UKMRC (2004) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985\u2013990. doi: 10.1016\/S0140-6736(05)67070-5","journal-title":"Lancet"},{"key":"2054_CR15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m A, Gr\u00f8nberg BHH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R, Nordic (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60\u00a0years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916\u2013926. doi: 10.1016\/S1470-2045(12)70265-6","journal-title":"Lancet Oncol"},{"key":"2054_CR16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","volume":"13","author":"W Wick","year":"2012","unstructured":"Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. The Lancet Oncology 13:707\u2013715. doi: 10.1016\/S1470-2045(12)70164-X","journal-title":"The Lancet Oncology"},{"key":"2054_CR17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-CC, Gorlia T, Hamou M-FF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff ROO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003. doi: 10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"2054_CR18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","volume":"31","author":"G Cairncross","year":"2013","unstructured":"Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337\u2013343. doi: 10.1200\/JCO.2012.43.2674","journal-title":"J Clin Oncol"},{"key":"2054_CR19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","volume":"31","author":"MJ Bent van den","year":"2013","unstructured":"van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre J-YY, Bernsen HJJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344\u2013350. doi: 10.1200\/JCO.2012.43.2229","journal-title":"J Clin Oncol"},{"key":"2054_CR20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","volume":"6","author":"MS Breemen van","year":"2007","unstructured":"van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421\u2013430. doi: 10.1016\/S1474-4422(07)70103-5","journal-title":"Lancet Neurol"},{"key":"2054_CR21","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M G\u00f6ttlicher","year":"2001","unstructured":"G\u00f6ttlicher M, Minucci S, Zhu P, Kr\u00e4mer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969\u20136978. doi: 10.1093\/emboj\/20.24.6969","journal-title":"EMBO J"},{"key":"2054_CR22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","volume":"64","author":"N Gurvich","year":"2004","unstructured":"Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS (2004) Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64:1079\u20131086","journal-title":"Cancer Res"},{"key":"2054_CR23","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","volume":"276","author":"CJ Phiel","year":"2001","unstructured":"Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734\u201336741. doi: 10.1074\/jbc.M101287200","journal-title":"J Biol Chem"},{"key":"2054_CR24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1124\/mol.105.014167","volume":"68","author":"MR Acharya","year":"2005","unstructured":"Acharya MR, Sparreboom A, Venitz J, Figg WD (2005) Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68:917\u2013932. doi: 10.1124\/mol.105.014167","journal-title":"Mol Pharmacol"},{"key":"2054_CR25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","volume":"34","author":"A Duenas-Gonzalez","year":"2008","unstructured":"Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206\u2013222. doi: 10.1016\/j.ctrv.2007.11.003","journal-title":"Cancer Treat Rev"},{"key":"2054_CR26","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","volume":"86","author":"CA Barker","year":"2013","unstructured":"Barker CA, Bishop AJ, Chang M, Beal K, Chan TA (2013) Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86:504\u2013509. doi: 10.1016\/j.ijrobp.2013.02.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2054_CR27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3109\/08880018.2011.563774","volume":"28","author":"FH Felix","year":"2011","unstructured":"Felix FH, Trompieri NM, de Araujo OL, da Trindade KM, Fontenele JB (2011) Potential role for valproate in the treatment of high\u2013risk brain tumors of childhood-results from a retrospective observational cohort study. Pediatr Hematol Oncol 28:556\u2013570. doi: 10.3109\/08880018.2011.563774","journal-title":"Pediatr Hematol Oncol"},{"key":"2054_CR28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3171\/2012.10.JNS12169","volume":"118","author":"GD Guthrie","year":"2013","unstructured":"Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg 118:859\u2013865. doi: 10.3171\/2012.10.JNS12169","journal-title":"J Neurosurg"},{"key":"2054_CR29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/neuonc\/not057","volume":"15","author":"M Kerkhof","year":"2013","unstructured":"Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, Vecht CJ (2013) Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 15:961\u2013967. doi: 10.1093\/neuonc\/not057","journal-title":"Neuro Oncol"},{"key":"2054_CR30","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","volume":"77","author":"M Weller","year":"2011","unstructured":"Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff ROO, Vecht CJ, Stupp R (2011) Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma. Neurology 77:1156\u20131164. doi: 10.1212\/WNL.0b013e31822f02e1","journal-title":"Neurology"},{"key":"2054_CR31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1634\/theoncologist.2008-0248","volume":"14","author":"JE Bromberg","year":"2009","unstructured":"Bromberg JE, van den Bent MJ (2009) Oligodendrogliomas: molecular biology and treatment. Oncologist 14:155\u2013163. doi: 10.1634\/theoncologist.2008-0248","journal-title":"Oncologist"},{"key":"2054_CR32","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/jnci\/90.19.1473","volume":"90","author":"JG Cairncross","year":"1998","unstructured":"Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473\u20131479","journal-title":"J Natl Cancer Inst"},{"key":"2054_CR33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejcb.2004.12.010","volume":"84","author":"H Hess-Stumpp","year":"2005","unstructured":"Hess-Stumpp H (2005) Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 84:109\u2013121. doi: 10.1016\/j.ejcb.2004.12.010","journal-title":"Eur J Cell Biol"},{"key":"2054_CR34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3747\/co.v15i5.371","volume":"15","author":"DR Walkinshaw","year":"2008","unstructured":"Walkinshaw DR, Yang XJ (2008) Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 15:237\u2013243","journal-title":"Curr Oncol"},{"key":"2054_CR35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2010.03.010","volume":"78","author":"C Blattmann","year":"2010","unstructured":"Blattmann C, Oertel S, Ehemann V, Thiemann M, Huber PE, Bischof M, Witt O, Deubzer HE, Kulozik AE, Debus J, Weber K-JJ (2010) Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 78:237\u2013245. doi: 10.1016\/j.ijrobp.2010.03.010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2054_CR36","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1158\/1078-0432.CCR-04-0537","volume":"10","author":"K Camphausen","year":"2004","unstructured":"Camphausen K, Scott T, Sproull M, Tofilon PJ (2004) Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 10:6066\u20136071. doi: 10.1158\/1078-0432.CCR-04-0537","journal-title":"Clin Cancer Res"},{"key":"2054_CR37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","volume":"62","author":"P Chinnaiyan","year":"2005","unstructured":"Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang S-MM, Harari PM (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62:223\u2013229. doi: 10.1016\/j.ijrobp.2004.12.088","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2054_CR38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1215\/15228517-2006-032","volume":"9","author":"M Entin-Meer","year":"2007","unstructured":"Entin-Meer M, Yang X, VandenBerg SR, Lamborn KR, Nudelman A, Rephaeli A, Haas-Kogan DA (2007) In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol 9:82\u201388. doi: 10.1215\/15228517-2006-032","journal-title":"Neuro Oncol"},{"key":"2054_CR39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","volume":"114","author":"K Camphausen","year":"2005","unstructured":"Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114:380\u2013386. doi: 10.1002\/ijc.20774","journal-title":"Int J Cancer"},{"key":"2054_CR40","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","volume":"14","author":"P Chinnaiyan","year":"2008","unstructured":"Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ (2008) Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14:5410\u20135415. doi: 10.1158\/1078-0432.CCR-08-0643","journal-title":"Clin Cancer Res"},{"key":"2054_CR41","doi-asserted-by":"crossref","first-page":"27586","DOI":"10.1074\/jbc.M303740200","volume":"278","author":"N Detich","year":"2003","unstructured":"Detich N, Bovenzi V, Szyf M (2003) Valproate induces replication-independent active DNA demethylation. J Biol Chem 278:27586\u201327592. doi: 10.1074\/jbc.M303740200","journal-title":"J Biol Chem"},{"key":"2054_CR42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","volume":"107","author":"KA Nifterik Van","year":"2012","unstructured":"Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ (2012) Valproic acid sensitizes human glioma cells for temozolomide and \u03b3-radiation. J Neurooncol 107:61\u201367. doi: 10.1007\/s11060-011-0725-z","journal-title":"J Neurooncol"},{"key":"2054_CR43","doi-asserted-by":"crossref","first-page":"42433","DOI":"10.1074\/jbc.M508270200","volume":"280","author":"A Matheu","year":"2005","unstructured":"Matheu A, Klatt P, Serrano M (2005) Regulation of the INK4a\/ARF locus by histone deacetylase inhibitors. J Biol Chem 280:42433\u201342441","journal-title":"J Biol Chem"},{"key":"2054_CR44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11060-008-9644-z","volume":"90","author":"A Idbaih","year":"2008","unstructured":"Idbaih A, Carvalho Silva R, Crini\u00e8re E, Marie Y, Carpentier C, Boisselier B, Taillibert S, Rousseau A, Mokhtari K, Ducray F, Thillet J, Sanson M, Hoang-Xuan K, Delattre J-YY (2008) Genomic changes in progression of low-grade gliomas. J Neurooncol 90:133\u2013140. doi: 10.1007\/s11060-008-9644-z","journal-title":"J Neurooncol"},{"key":"2054_CR45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1750-3639.2006.00030.x","volume":"17","author":"T Watanabe","year":"2007","unstructured":"Watanabe T, Katayama Y, Yoshino A, Yachi K, Ohta T, Ogino A, Komine C, Fukushima T (2007) Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol 17:5\u201310","journal-title":"Brain Pathol"},{"key":"2054_CR46","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","volume":"22","author":"OH Kramer","year":"2003","unstructured":"Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, Brill B, Groner B, Bach I, Heinzel T, Gottlicher M (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22:3411\u20133420","journal-title":"EMBO J"},{"key":"2054_CR47","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/1471-2407-8-243","volume":"8","author":"AK Lucio-Eterovic","year":"2007","unstructured":"Lucio-Eterovic AK, Cortez MAA, Valera ET, Motta FJ, Queiroz RG, Machado HR, Carlotti CG, Neder L, Scrideli CA, Tone LG (2007) Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 8:243. doi: 10.1186\/1471-2407-8-243","journal-title":"BMC Cancer"},{"key":"2054_CR48","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood-2012-10-461988","volume":"121","author":"F Santoro","year":"2013","unstructured":"Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, Barozzi I, Senese S, Fornasari L, Moretti S, Altucci L, Pelicci PG, Chiocca S, Johnstone RW, Minucci S (2013) A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121:3459\u20133468. doi: 10.1182\/blood-2012-10-461988","journal-title":"Blood"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-016-2054-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-016-2054-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-016-2054-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T19:05:58Z","timestamp":1654196758000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-016-2054-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["2054"],"URL":"https:\/\/doi.org\/10.1007\/s11060-016-2054-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]}}}